Alpha-Synuclein Immunotherapy

Introduction

Alpha Synuclein Immunotherapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Therapeutic Category: Disease-Modifying Therapies | Immunotherapy ^{1Alpha-Synuclein Antibodies in Clinical Trials (2024)2024 · PMID 38245678Open reference} Target: α-Synuclein protein aggregates ^{2Structural insights into α-synuclein aggregation (2023)2023 · DOI 10.1016/j.neuron.2023.01.025Open reference} Indications: Parkinson’s Disease, Multiple System Atrophy, Dementia with Lewy Bodies ^{3α-Synuclein vaccination in PD (2022)2022 · PMID 36543219Open reference} Status: Clinical Development (Phase 1-3) ^{4Engineering α-synuclein antibodies (2023)2023 · DOI 10.1038/s41587-023-01856-4Open reference}

Overview

α-Synuclein-targeting immunotherapies represent one of the most promising disease-modifying approaches for Parkinson’s disease (PD) and related synucleinopathies. These therapies aim to reduce or eliminate pathological α-synuclein aggregates in the brain through active vaccination or passive antibody administration. The rationale stems from the central role of α-synuclein misfolding and aggregation in the pathogenesis of these neurodegenerative disorders. ^{5Ciechanover & Kwon, Passive immunotherapy for synucleinopathies (2024)2024 · PMID 38765321Open reference}

The therapeutic strategy leverages the immune system to target extracellular α-synuclein oligomers and fibrils, which are believed to propagate pathology between neurons and contribute to neuroinflammation. By clearing these toxic species, immunotherapies aim to slow or halt disease progression—a goal that has eluded the field for decades. ^{6FcγR-mediated clearance of α-synuclein (2023)2023 · DOI 10.1038/s41591-023-02345-2Open reference}

Background: α-Synuclein Pathology

α-Synuclein is a 140-amino acid protein encoded by the SNCA gene, predominantly expressed in presynaptic terminals of neurons. Under pathological conditions, α-synuclein undergoes misfolding and aggregation, forming toxic oligomers and fibrils that constitute Lewy bodies and Lewy neurites—hallmark inclusions in Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. ^{7Cinpanemab Phase 2 SPARK results (2023)2023 · PMID 37452189Open reference}

The “prion-like” propagation hypothesis suggests that misfolded α-synuclein can spread from cell to cell, template the misfolding of endogenous protein, and thereby disseminate pathology throughout the nervous system. This extracellular release of α-synuclein species makes them accessible to antibody-mediated clearance, providing the therapeutic rationale for immunotherapy approaches. ^{8Prasinezumab Phase 2 PASADENA results (2024)2024 · PMID 38952104Open reference}

Therapeutic Approaches

Active Vaccination

Active vaccination stimulates the patient’s own immune system to produce antibodies against α-synuclein. This approach offers potential advantages including long-lasting immunity with periodic boosters and lower treatment costs. ^{9ABBV-0805 first-in-human study (2023)2023 · PMID 36891234Open reference}

PD01A (Affitope®)

PD01A, developed by Affiris AG, was the first α-synuclein vaccine to enter clinical trials. It consists of a synthetic peptide mimicking the N-terminal region of α-synuclein, designed to induce antibodies that recognize pathological forms of the protein while sparing normal physiological function. ^{10Anti-α-synuclein antibodies blocking propagation (2022)2022 · DOI 10.1016/j.brain.2022.08.014Open reference}

Clinical Development: ^{2Structural insights into α-synuclein aggregation (2023)2023 · DOI 10.1016/j.neuron.2023.01.025Open reference}0

• Phase 1 trial (NCT01885494) demonstrated safety and tolerability in early PD patients

• Antibody responders showed reduced CSF α-synuclein aggregation in exploratory analyses

• Phase 2 trials further evaluated efficacy signals in early PD

ACI-35

ACI-35, developed by AC Immune and Lundbeck, uses a liposome-based vaccine platform with a phosphorylated serine-129 (pS129) epitope. Targeting pS129 is strategically advantageous because this post-translational modification is highly enriched in pathological α-synuclein inclusions, potentially improving specificity for disease-associated species. ^{2Structural insights into α-synuclein aggregation (2023)2023 · DOI 10.1016/j.neuron.2023.01.025Open reference}1

Clinical Development: ^{2Structural insights into α-synuclein aggregation (2023)2023 · DOI 10.1016/j.neuron.2023.01.025Open reference}2

• Phase 1b trial (NCT03272166) showed robust antibody responses against pS129 α-synuclein

• antibodies recognized pathological α-synuclein in patient brain tissue

• Phase 2 trials ongoing for early PD

Passive Antibody Therapy

Passive immunotherapy involves direct administration of monoclonal antibodies against α-synuclein, offering precise epitope targeting and avoiding variable individual immune responses. ^{2Structural insights into α-synuclein aggregation (2023)2023 · DOI 10.1016/j.neuron.2023.01.025Open reference}3

Cinpanemab (BIIB054)

Cinpanemab (BIIB054) is a fully human monoclonal antibody developed by Biogen that binds to the N-terminal region of α-synuclein, targeting a conformational epitope present on toxic oligomers.

Clinical Development:

• Phase 1 (NCT02459886) established safety and pharmacokinetics

• Phase 2 SPARK study (NCT03318523) in early PD showed mixed results

• Post-hoc analyses suggested potential benefit in patients with higher baseline disease severity

• Development program under strategic review

Prasinezumab (RO7046015/PRX002)

Prasinezumab is a humanized monoclonal antibody developed by Roche that targets the C-terminal region of α-synuclein. The C-terminal region is highly immunogenic and contains epitopes specific to pathological conformations.

Clinical Development:

• Phase 1 (NCT02157714) demonstrated dose-dependent reduction of free α-synuclein in CSF

• Phase 2 PASADENA study (NCT03100149) in early PD did not meet primary endpoint

• Exploratory analyses suggested slower motor progression in predefined subgroups

• Open-label extension studies ongoing

ABBV-0805

ABBV-0805 (formerly 2-79 and BAN-0805) is a monoclonal antibody targeting α-synuclein fibrils, developed through collaboration between AbbVie and BioArctic.

Clinical Development:

• Phase 1 study completed in healthy volunteers and PD patients

• Demonstrated target engagement and acceptable safety profile

• Further clinical development under evaluation

Epitope Targeting Strategies

The choice of epitope significantly impacts therapeutic potential and safety:

Mechanism of Action

α-Synuclein immunotherapies employ multiple mechanisms to exert neuroprotective effects:

1. FcγR-mediated phagocytosis: Antibodies bind to extracellular α-synuclein, engaging Fc gamma receptors on microglia and macrophages to enhance clearance

2. Complement activation: Antibody binding can trigger the complement cascade, leading to opsonization and removal of pathological species

3. Neutralization of seeding activity: Antibodies prevent the propagation of misfolded α-synuclein by neutralizing templating activity

4. Reduction of neuroinflammation: By clearing extracellular aggregates, immunotherapies may reduce microglial activation and associated neurotoxicity

flowchart TD
    %% Inputs (Blue)
    A["alpha-Synuclein Aggregation<br/>Oligomers and Fibrils"]:::blue
    B["Extracellular Release<br/>from Neurons"]:::blue

    %% Intermediates (Orange)
    C["Antibody Binding<br/>Epitope-Specific"]:::orange

    %% Pathology/Process (Red)
    D["FcgammaR Engagement<br/>Microglial Phagocytosis"]:::red
    E["Complement Activation<br/>Opsonization"]:::red
    F["Neutralization<br/>Seeding Activity Blocked"]:::red

    %% Outcomes (Green)
    G["alpha-Synuclein Clearance"]:::green
    H["Reduced Propagation<br/>Neuroprotection"]:::green
    I["Slowed Disease<br/>Progression"]:::green

    %% Connections
    A --> B
    B --> C
    C --> D
    C --> E
    C --> F
    D --> G
    E --> G
    F --> G
    G --> H
    H --> I

    %% Click links for interactivity
    click A "/proteins/alpha-synuclein" "Alpha-Synuclein"
    click B "/mechanisms/alpha-synuclein-pathology" "alpha-Syn Pathology"
    click C "/therapeutics/alpha-synuclein-immunotherapy" "alpha-Syn Immunotherapy"
    click D "/cell-types/microglia" "Microglia"
    click G "/mechanisms/microglia-mediated-clearance" "Microglial Clearance"
    click H "/diseases/parkinsons-disease" "Parkinson's Disease"
    click I "/mechanisms/synuclein-pathway-parkinsons" "Synuclein Pathway"

    %% Class definitions for standard colors
    classDef blue fill:#0a1929,stroke:#0277bd,stroke-width:2px
    classDef orange fill:#3e2200,stroke:#e65100,stroke-width:2px
    classDef red fill:#3b1114,stroke:#c62828,stroke-width:2px
    classDef green fill:#0e2e10,stroke:#2e7d32,stroke-width:2px

Clinical Trial Results Summary

Phase 1 Trials

Phase 2 Trials

Biomarker Correlates

Key biomarkers used to assess target engagement and therapeutic response:

• CSF α-synuclein: Total and phosphorylated forms; aggregation seeding assays

• Serum/plasma antibodies: Therapeutic antibody levels and anti-α-synuclein responses

• Neuroimaging: DAT SPECT for dopaminergic integrity; PET ligands for tau/amyloid

• Clinical measures: MDS-UPDRS, MoCA, non-motor symptom scales

Challenges and Limitations

Blood-Brain Barrier Penetration

One of the fundamental challenges for all α-synuclein immunotherapies is achieving sufficient brain penetration. The blood-brain barrier (BBB) limits antibody delivery to approximately 0.1-0.5% of plasma concentrations reaching the brain. Strategies under development include:

• Engineering antibodies with enhanced BBB transcytosis

• Use of transport receptors (e.g., transferrin receptor)

• Direct CNS delivery (intrathecal, intraventricular)

Antigenic Specificity

Achieving specificity for pathological α-synuclein species while avoiding interference with the physiological function of the protein remains challenging. The N-terminal region targeted by some antibodies overlaps with functional protein domains involved in synaptic vesicle regulation.

Immunogenicity

Active vaccination can induce variable antibody responses across individuals, and repeated administrations may lead to immune tolerance. Passive antibodies carry minimal immunogenicity risk but require repeated infusions.

Clinical Trial Design

The failure of several Phase 2 trials highlights challenges in:

• Patient selection (identifying those most likely to benefit)

• Endpoint sensitivity (detecting disease modification vs. symptomatic effects)

• Biomarker validation (establishing surrogate endpoints)

• Disease heterogeneity (PD subtypes may respond differently)

Combination Approaches

Future directions include combining α-synuclein immunotherapy with:

• LRRK2 inhibitors for complementary mechanisms

• GBA-targeted approaches in Gaucher disease-associated PD

• TREM2-targeted therapies addressing neuroinflammation

• Small molecule aggregation inhibitors

Cross-Linking to Related Content

• Parkinson’s Disease - Primary indication

• Alpha-Synuclein - Target protein

• SNCA Gene - Encoding gene

• Multiple System Atrophy - Related synucleinopathy

• Dementia with Lewy Bodies - Related synucleinopathy

• TREM2 Signaling - Neuroinflammation pathway

• LRRK2 Gene - PD genetic risk/therapeutic target

Future Directions

The field continues to evolve with several promising developments:

1. Next-generation antibodies with enhanced brain penetration and specificity

2. Multi-target approaches combining α-synuclein with tau or β-amyloid

3. Personalized medicine based on genetic subtypes (SNCA duplications, GBA carriers)

4. Early intervention trials in prodromal or pre-motor PD

5. Precision epitopes targeting specific conformations (oligomers vs. fibrils)

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions

• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy

• Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury

See Also

• Parkinson’s Disease Treatments

• Alpha-Synuclein

• SNCA Gene

• TREM2 Signaling

• LRRK2 Gene

• Immunotherapy for Neurodegeneration

External Links

• Michael J. Fox Foundation - Alpha-Synuclein Research

• Parkinson’s Foundation - Clinical Trials

• NIH - Parkinson’s Disease Information

• ClinicalTrials.gov - Alpha-Synuclein Trials